The proposed bill, known as the Patient Protection Act, seeks to enact section 3715.39 of the Revised Code, which aims to regulate the sale and prescription of certain drugs that can cause severe adverse effects. The bill defines "severe adverse effects" to include conditions such as death, hospitalization due to infection or hemorrhaging, organ failure, and sepsis. It prohibits retailers and terminal distributors of dangerous drugs from selling or offering drugs available without a prescription if they cause severe adverse effects in more than five percent of users. Additionally, it restricts the sale of such drugs by mail and establishes conditions for prescribers, requiring them to conduct in-person examinations, inform patients about the risks, and schedule follow-up appointments before issuing prescriptions.

The bill also designates the director of health as responsible for determining which drugs meet the criteria for severe adverse effects, requiring consultation with relevant state officials and reliance on data from insurance claims, patient reports, and the FDA. The director is tasked with maintaining and publicly updating a list of drugs that cause severe adverse effects in more than five percent of users, ensuring transparency and public access to this information.